Streptococcus pneumoniae triggers progression of pulmonary fibrosis through pneumolysin

Thorax. 2015 Jul;70(7):636-46. doi: 10.1136/thoraxjnl-2014-206420. Epub 2015 May 11.

Abstract

Rationale: Respiratory tract infections are common in patients suffering from pulmonary fibrosis. The interplay between bacterial infection and fibrosis is characterised poorly.

Objectives: To assess the effect of Gram-positive bacterial infection on fibrosis exacerbation in mice.

Methods: Fibrosis progression in response to Streptococcus pneumoniae was examined in two different mouse models of pulmonary fibrosis.

Measurements and main results: We demonstrate that wild-type mice exposed to adenoviral vector delivery of active transforming growth factor-β1 (TGFß1) or diphteria toxin (DT) treatment of transgenic mice expressing the DT receptor (DTR) under control of the surfactant protein C (SPC) promoter (SPC-DTR) to induce pulmonary fibrosis developed progressive fibrosis following infection with Spn, without exhibiting impaired lung protective immunity against Spn. Antibiotic treatment abolished infection-induced fibrosis progression. The cytotoxin pneumolysin (Ply) of Spn caused this phenomenon in a TLR4-independent manner, as Spn lacking Ply (SpnΔply) failed to trigger progressive fibrogenesis, whereas purified recombinant Ply did. Progressive fibrogenesis was also observed in AdTGFβ1-exposed Ply-challenged TLR4 KO mice. Increased apoptotic cell death of alveolar epithelial cells along with an attenuated intrapulmonary release of antifibrogenic prostaglandin E2 was found to underlie progressive fibrogenesis in Ply-challenged AdTGFβ1-exposed mice. Importantly, vaccination of mice with the non-cytotoxic Ply derivative B (PdB) substantially attenuated Ply-induced progression of lung fibrosis in AdTGFβ1-exposed mice.

Conclusions: Our data unravel a novel mechanism by which infection with Spn through Ply release induces progression of established lung fibrosis, which can be attenuated by protein-based vaccination of mice.

Keywords: Bacterial Infection; Idiopathic pulmonary fibrosis; Respiratory Infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use
  • Apoptosis / drug effects
  • Bacterial Proteins / pharmacology
  • Bacterial Proteins / physiology
  • Bronchoalveolar Lavage Fluid / immunology
  • Diphtheria Toxin
  • Disease Models, Animal
  • Disease Progression
  • Epithelial Cells / drug effects
  • Female
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mice, Transgenic
  • Pneumococcal Vaccines
  • Pneumonia, Pneumococcal / complications*
  • Pneumonia, Pneumococcal / drug therapy
  • Pneumonia, Pneumococcal / immunology
  • Pneumonia, Pneumococcal / metabolism
  • Pulmonary Alveoli / drug effects
  • Pulmonary Alveoli / pathology
  • Pulmonary Fibrosis / immunology
  • Pulmonary Fibrosis / metabolism
  • Pulmonary Fibrosis / microbiology*
  • Pulmonary Fibrosis / prevention & control
  • Streptolysins / deficiency
  • Streptolysins / pharmacology
  • Streptolysins / physiology*
  • Transforming Growth Factor beta1 / metabolism

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Diphtheria Toxin
  • Pneumococcal Vaccines
  • Streptolysins
  • Transforming Growth Factor beta1
  • plY protein, Streptococcus pneumoniae